^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | AV-GBM-1 (Immunostimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
331 Tumor markers associated with increased survival in a phase II trial of dendritic cell/tumor-initiating-cell vaccine AV-GBM-1 in patients with newly diagnosed glioblastoma
Published date:
11/09/2021
Excerpt:
18-month OS rates were 59% vs 35% for MGMT promotor methylation, 71% vs 40% for IDH mutation and 58% vs 32% for either. Both MGMT promotor methylation and IDH mutation were associated with a substantial and similar survival benefit in primary GBM patients treated with AV-GBM-1 in addition to standard aggressive therapy.
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.331
Trial ID:
